These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17576054)

  • 1. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate.
    Shakweh M; Bravo-Osuna I; Ponchel G
    Eur J Pharm Sci; 2007 Aug; 31(5):262-70. PubMed ID: 17576054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disintegration/dissolution profiles of copies of Fosamax (alendronate).
    Epstein S; Cryer B; Ragi S; Zanchetta JR; Walliser J; Chow J; Johnson MA; Leyes AE
    Curr Med Res Opin; 2003; 19(8):781-9. PubMed ID: 14687450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2009 Feb; 25(2):449-52. PubMed ID: 19192989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports].
    Tóth E; Fork FT; Lindelöw K; Lindström E; Verbaan H; Veress B
    Lakartidningen; 1998 Aug; 95(35):3676-80. PubMed ID: 9748782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate-associated esophageal injury: pathologic and endoscopic features.
    Abraham SC; Cruz-Correa M; Lee LA; Yardley JH; Wu TT
    Mod Pathol; 1999 Dec; 12(12):1152-7. PubMed ID: 10619269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
    Peter CP; Handt LK; Smith SM
    Dig Dis Sci; 1998 Sep; 43(9):1998-2002. PubMed ID: 9753265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
    Walker AD; Adachi JD
    Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition.
    Lamprecht G
    J Pharm Sci; 2009 Oct; 98(10):3575-81. PubMed ID: 19630066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buccoadhesive tablets for insulin delivery: in-vitro and in-vivo studies.
    Hosny EA; Elkheshen SA; Saleh SI
    Boll Chim Farm; 2002; 141(3):210-7. PubMed ID: 12197420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics.
    Singh B; Pahuja S; Kapil R; Ahuja N
    Acta Pharm; 2009 Mar; 59(1):1-13. PubMed ID: 19304554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate.
    Hodges LA; Connolly SM; Winter J; Schmidt T; Stevens HN; Hayward M; Wilson CG
    Int J Pharm; 2012 Aug; 432(1-2):57-62. PubMed ID: 22564778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Esophageal lesions associated with diphosphonates].
    Larsen KO; Stray N; Engh V; Sandnes D
    Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2397-9. PubMed ID: 11475224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Process analytical technology to understand the disintegration behavior of alendronate sodium tablets.
    Xu X; Gupta A; Sayeed VA; Khan MA
    J Pharm Sci; 2013 May; 102(5):1513-23. PubMed ID: 23450666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: design, in vitro and 'in vivo' evaluation.
    Wang L; Tang X
    Int J Pharm; 2008 Feb; 350(1-2):181-7. PubMed ID: 17920795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on Disintegration/dissolution profiles of copies of Fosamax (alendronate).
    Bolaños Díaz R
    Curr Med Res Opin; 2004 Jul; 20(7):1035-6; author reply 1036-7. PubMed ID: 15265248
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid determination of alendronate to quality evaluation of tablets by high resolution ¹H NMR spectroscopy.
    Xie B; Liu A; Fang X; Chen Y; Zhong H
    J Pharm Biomed Anal; 2014 May; 93():73-6. PubMed ID: 24215933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.